rVSV-ZEBOV will protect against Ebola
Experimental Ebola vaccine has shown 100% effectiveness
An experimental Ebola vaccine tested in African Guinea showed almost 100% effectiveness, the World Health Organization (Final trial results confirm Ebola vaccine provides high protection against disease - VM) reported, citing the final data of the study published in the Lancet journal (Henao–Restrepo et al., Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomized trial (Ebola Ça Suffit!) – VM).
According to WHO, almost six thousand residents of Guinea received the new rVSV-ZEBOV vaccine and none of them became infected with the dangerous virus. At the same time, 23 cases of the disease were detected in a comparable group of patients who had not been vaccinated.
The rVSV-ZEBOV vaccine was developed by the Canadian Ministry of Health, and then the license for its production and testing was transferred to the international pharmaceutical research company Merck & Co.
Ebola virus disease is an acute viral infection affecting humans and some animal species. The Ebola epidemic in West Africa mainly affected three countries: Guinea, Sierra Leone and Liberia.
Portal "Eternal youth" http://vechnayamolodost.ru 23.12.2016